Skip to main content
Tinavi Medical Technologies Co.,Ltd. logo

Tinavi Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688277 ISIN · CNE100004256 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 759 across all filing types
Latest filing 2026-05-22 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688277

About Tinavi Medical Technologies Co.,Ltd.

https://www.tinavi.com/

Tinavi Medical Technologies Co.,Ltd. specializes in the design, development, and commercialization of orthopedic surgical robotic systems. Its primary offering, the TiRobot system, provides a multi-functional platform for spine and trauma surgeries, supporting procedures such as pedicle screw fixation and pelvic fracture reduction. The technology incorporates high-definition 3D imaging, precise mechanical arms, and advanced navigation software to facilitate minimally invasive operations with sub-millimeter accuracy. By integrating preoperative planning with real-time intraoperative guidance, the system aims to enhance surgical precision, reduce recovery times, and minimize radiation exposure for clinical teams. The company focuses on delivering intelligent robotic solutions to hospitals and specialized surgical centers to improve the consistency and safety of complex orthopedic interventions.

Recent filings

Filing Released Lang Actions
关于2025年年度股东会增加临时提案的公告
Proxy Solicitation & Information Statement Classification · 90% confidence The document is an official shareholder meeting announcement detailing the addition of a temporary proposal to the 2025 Annual General Meeting, including full proposal descriptions, meeting logistics, and an attached proxy authorization form (“授权委托书”). It is a pre-meeting communication providing information and soliciting votes, fitting the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-22 Chinese
关于预计2026年度日常关联交易的公告
Regulatory Filings Classification · 75% confidence The document is an official announcement by Beijing Tianzhihang Medical Technology Co., Ltd. regarding its expected 2026 ordinary related‐party transactions. It describes board approvals, transaction amounts, counterparties, and compliance with listing rules. There is no substantive financial report or investor presentation, nor is it an earnings release or dividend notice. It is a routine disclosure under exchange regulations, with no specific category for related‐party transaction forecasts. Therefore, it falls into the general “Regulatory Filings” category as a compliance announcement.
2026-05-22 Chinese
第六届董事会第三十二次会议决议公告
Regulatory Filings Classification · 75% confidence The document is a “董事会决议公告” (Board of Directors meeting resolution announcement) detailing the convocation, attendance, and resolutions of the company’s sixth board meeting (e.g., reappointment of auditor, approval of related-party transactions, and 2026 remuneration scheme). It does not change board composition or senior management, nor is it a financial report or earnings release. This type of regulatory disclosure falls under the general regulatory announcements category.
2026-05-22 Chinese
关于补选第六届董事会非独立董事的公告
Board/Management Information Classification · 93% confidence The document is an official announcement by Beijing Tianzhihang Medical Technology Co., Ltd. regarding the nomination and supplementary election of a non-independent director to its sixth board, detailing the candidate’s qualifications and related board governance process. It clearly pertains to changes in the company’s board of directors, matching the definition for Board/Management Information (MANG).
2026-05-13 Chinese
关于2024年限制性股票激励计划第一个归属期符合归属条件的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official corporate announcement detailing the vesting and issuance of restricted stock under the company’s 2024 equity incentive plan. It is not a full annual or interim report, nor a dividend, proxy, or earnings release. Instead, it describes a share issue to employees under a restricted stock plan — a capital change. Under the filing definitions, announcements of new share issues or other capital structure changes fall under Share Issue/Capital Change (SHA).
2026-05-13 Chinese
关于作废2024年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Share Issue/Capital Change Classification · 78% confidence The document is a corporate announcement by Beijing Tianzhihang Medical Technology Co. regarding the cancellation (voiding) of unvested restricted shares under its 2024 stock incentive plan. It details board and shareholder approvals and the specific volume of shares being voided—i.e., a change to the company’s capital structure rather than the publication of a financial report or management change. This fits the “Share Issue/Capital Change (SHA)” category as it concerns an adjustment to the company’s share capital.
2026-05-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.